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Abstract 
 
Environmental risk assessment (ERA) is mandatory for all new applications for centralized marketing 
authorization or national regardless of their legal basis. ERA aims to protect the environment. Risk assessment 
has two phases of veterinary product evaluation possible role of exposure and its effects. Phase I of the ERA is 
based on filling a decision tree with 19 questions. If the answers to these questions do not stop the assessment 
at this stage then is advancing to Phase II. It uses a two stage approach stage A and stage B. The first stage, 
stage A, studies using simple, less expensive studies. I f the assessment is not complete, then is appealed to 
Step B to drill ERA. If there is still a risk indicator after filling and assessment in stage B, then, to mitigate risk, is 
recommended the file discussing and of the proposals for additional data. 
 
Rezumat 
 
Evaluarea Riscului pentru Mediu (ERA) este obligatorie pentru toate aplicatiile noi pentru o autorizare de 
comercializare centralizata sau nationala indiferent de baza legala a acestora. ERA vizeaza protectia mediului 
inconjurator. Evaluarea Riscului are doua faze de evaluarea posibilului rol, expunerii si efectelor produsului. Faza 
I a ERA se bazeaza pe o completare a unui arbore decizional cu 19 intrebari. Daca raspunsuri le la aceste 
intrebari nu opresc evaluarea in acest stadiu, atunci se avanseaza la Faza II. Se utilizeaza o abordare in doua 
trepte Treapta A si Treapta B. Prima treapta, Treapta A, utilizeaza studii simple, mai putin costisitoare. Daca 
evaluarea nu este completa, atunci se trece la Treapta B pentru a detalia ERA. Daca exista in continuare o 
indiciu de risc si dupa completarea si a evaluarii in Treapta B, atunci se recomanda discutarea dosarului si a 
propunerilor pentru date suplimentare sau pentru atenuarea riscului. 
 
1. Structure of E.R.A. of veterinary 
medicinal products 
 
Risk assessment is an evaluation of the 
possible fate, exposure and effects of the 
product.  
As a whole, the risk assessment is 
structured around the risk quotient approach 
as described in VICH guidelines GL6 (Phase 
I) and GL38 (Phase II). The risk quotient 
(RQ) is defined as the ratio between the 
predicted  environmental  concentration 
(PEC)  and  the  predicted  no-effect 
concentration (PNEC). If reliable monitoring 
data are available, these may replace the 
predicted values. The risk quotients indicate 
the likelihood of adverse effects occurring.  
In Phase I, the investigator shall assess 
the potential extent of exposure of the 
environment to the product, its active 
substances and other ingredients, taking into 
account: 
• The target species, and the proposed 
pattern of use 
• Characteristics of the constituents of 
the VMP 
• The method of administration 
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In Phase I several exemptions from 
further testing are incorporated.  
When these exemptions do not apply, 
and trigger values are exceeded, one enters 
Phase II.  
As appropriate, further investigation 
may be required of: 
 
• Fate and behaviour in soil, water and 
dung 
• Effects on aquatic organisms 
• Effects on other non-target organisms 
 
The Phase II assessment starts at Tier 
A with a base data set on fate and effects 
that allows for risk characterisation.  
If a risk cannot be excluded the 
assessment proceeds to Tier B.  
The VICH documents present a set of 
Phase II Tier B fate and effects studies.  
 
2. Environment’s exposure to the V.M.P.s 
 
The route and quantity of a VMP 
entering the environment determines the risk 
assessment scenarios that are applicable 
and the extent of the risk assessment.  
Emission can occur at various stages in 
the life cycle of the product.  
However, with the exception of certain 
topicals or those added directly to water, 
most VMPs first pass through the animal to 
which it is administered.  
Generally  the  most  significant 
environmental  exposure  results  from 
excretion of the active substance being the 
parent and/or its metabolites.  
Following  excretion,  residues  are 
generally  assumed  to  be  uniformly 
distributed in the environment. 
The route and quantity by which a VMP 
enters the environment determines the type 
of assessment (Phase I or Phase II) and the 
scenarios to be used.  
Dosage, route of application, type of 
target animals, excretion, route of entry into 
the environment and agricultural practice all 
influence the point at which environmental 
exposure occurs.  
 
The main scenarios are: 
 
•  Removal of material containing the 
product (manure, dirty water, fish farm 
effluent) 
• Excretion via faeces and urine (grazing 
animals) 
• Spillage at external application and/or 
direct exposure outdoors 
Based on the husbandry conditions, the 
following possible exposure routes are 
identified (Table 1). 
 
Table 1.  
Predominant exposure routes of veterinary medicines in key livestock species 
 
Livestock category  Slurry 
application 
Grazing 
animals 
Loss at application/ 
exposure outdoors 
Direct entry into 
water* 
cattle  X  X  X  X 
pigs  X       
horses and ponies  X  X     
sheep/goats    X  X  X 
poultry  X       
fish farms  X      X 
 
* this can mean direct excretion, loss from the fleece/hide or direct entry of the veterinary medicine 
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Figure 1. The VMP’s turnover in the environment 
 
3. Environmental distribution 
 
The route of distribution and the fate in 
the environment are important for the final 
exposure concentration.  
For veterinary medicinal products, the 
predominant routes of exposure for the 
terrestrial and aquatic environment are 
through the application of manure, dung and 
urine.  
Distribution of the product occurs within 
the directly exposed compartment(s) and 
between different compartments.  
The terrestrial environment is exposed 
via: 
• Direct excretion of dung and urine; 
• Loss from animals treated topically; 
• Spreading of contaminated slurry and/or 
sludge. 
• The aquatic environment is exposed via: 
•  Leaching, run-off and drainage from 
manured land; 
• Direct spillage and/or feed spillage; 
•  Direct excretion into water (pasture 
animals); 
• Direct application in water (aquaculture); 
•  Direct discharge of waste water into 
surface water (indoor aquaculture); 
• Release from Sewage Treatment Plants 
(indoor aquaculture). 
In  Phase I, the potential for 
environmental exposure is assessed based 
on the intended use of the VMP.  
It is assumed that VMPs with limited use 
and limited environmental exposure will 
have limited environmental effects and thus 
stop in Phase I.  
Phase I also identifies VMPs that 
require a more extensive ERA under Phase 
II. The Phase I ERA for a VMP makes use of 
the decision tree.  
To use the Phase I decision tree, the 
applicant works through the questions until 
they arrive at a question which allows them 
to conclude that their product qualifies for a 
Phase I report.  
If there is no information on a particular 
question, the question is ignored and the 
applicant continues to the next question. 
 
4. Predicted environmental 
concentration 
- Question 17 from the decision tree 
 
Question 17. – „Is the predicted 
environmental concentration of the VMP 
in soil (PECsoil) less than 100 µg kg
-1?” 
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In Phase I the total residue approach is 
applied. This means that the total amount of 
the dose applied is excreted from the animal 
and data on metabolism / excretion should 
not be taken into account.  
Food producing species can be raised 
indoors for all or a major part of their lives or 
they can be kept outdoors for all or a major 
part of their lives.  
The calculation of the initial PEC in soil 
is performed when more than a “small 
number of animals” are treated. 
 
PECsoil initial for intensively reared 
animals 
 
Intensively reared animals are those 
which are housed indoors throughout the 
production cycle so treatment with the VMP 
is carried out in housing and the active 
residue is excreted in the stable and is 
incorporated in the manure.  
This active residue reaches the 
environment when the manure from the 
stable is spread onto land. 
Calculation of the PECsoil initial for 
intensively reared animals is dependent on 
the quantity of manure containing active 
residue, which can be spread onto land.  
Based on the EUROSTAT database a 
nitrogen load of 170 kg N / ha is on average 
the maximum load in the most EU countries. 
The PECsoil initial should be calculated 
using the following equation: 
 
PECsol initial=   D x Ad x BW x P x 170 x Fh   x 1000   (Eq.1) 
                    1500 x 10000 x 0.05 x Ny x H  
 
Where: 
 
• PECsoil initial = Predicted Environmental Concentration 
in soil [µg.kg
-1] 
•  D = Daily dose of the active ingredient [mg.kgbw
-1.d
-1] 
• Ad = Number of days of treatment [d] 
•  BW = Animal body weight [kgbw] (see Table 3.) 
• P = Animal turnover rate per place per year [place
-1.y
-1] 
(see Table 3.) 
•  170 = EU nitrogen spreading limit [kg N.ha
-1] 
• Fh = Fraction of herd treated [value between 0 and 1] 
(see Table 2.) 
• 1500 = Bulk density of dry soil [kg.m
-3] 
•  10000 = Area of 1 hectare [m
2 .ha
-1] 
• 0.05 = Depth of penetration into soil [m] 
• Ny = Nitrogen produced in one year per place [kg.N. 
place
-1.y
-1] (see Table 3.) 
•  H = Housing factor either 1 for animals housed 
throughout the year or 0.5 for animals housed for only 6 
months (see Table 3.) 
•  1000 = Conversion factor [1000 µg.mg
-1] 
 
In this equation the only inputs required 
from the user are the dose rate and the 
number of administrations of the veterinary 
medicine in a course of treatment.  
These parameters will be available from 
the product’s SPC. 
Table 2. 
Percentage herd treatment for various groups of VMPs 
 
Product group  % herd 
treatment 
Anthelmintics  100 
Products for treatment of diarrhoea in calves, lambs and 
pigs (excluding products administered in feed and water) 
30 
Coccidiostatics  100 
Ectoparasiticides  100 
Intramammary preparations: 
                                                   for drying off 
                                         in lactating animals 
 
100 
25 
Antibiotics (feed and water medication)  100 
Antibiotics (injectable) 
                                             all pig treatments 
                         respiratory infections in cattle 
                                              foot rot in sheep 
 
50 
50 
100 
Teat dip and sprays  100 
All products for poultry  100 
All products for fish  100 
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Table 3.  
Default values for use in calculating the PECsoil for intensively reared animals 
 
Animal type 
Number of 
animals raised 
per place per 
year 
Bodyweight 
(kg) 
Nitrogen produced in 
1 year per place 
(kg.N.y
-1) 
Housing 
factor
1 
Calf  1.8  140  10  1 
Dairy cow   1  425  60  0.5 
Cattle (0-1 year)  1  200  18  0.5 
Cattle (>2 years)  1  450  35  0.5 
Weaner pig (to 25 kg)   6.9  12.5  2.25  1 
Fattening pig (25-125 kg)  3  65  7.5  1 
Sow (with litter)   1  240  262  1 
Broiler   9  1  0.23  1 
Laying hen  1  1.6  0.35  1 
Replacement layer   2.6  0.8  0.24  1 
Broiler breeder   1  1.7  0.69  1 
Turkey   2.7  6.5  0.9  1 
Duck   7  1.6  0.41  1 
Horse   1  400  35  0.5 
Rabbit   8  1.4  0.352  1 
 
PECsoil initial for pasture animals 
 
Pasture animals are those, which are 
on pasture throughout the production cycle 
so treatment with the veterinary medicine is 
carried out in the field and the residue of the 
veterinary medicine, is excreted directly onto 
the soil. 
Calculation of the PECsoil initial for 
pasture animals is dependent on the number 
of animals kept on any area of land. This 
parameter is known as the stocking density 
and is expressed in animals per hectare. 
 
PECsol initial =     D x Ad x BW x SD x Fh   x 1000 (Eq. 2) 
                           1500 x 10000 x 0.05  
Where: 
•  PEC soil initial = Predicted Environmental Concentration in 
soil [µg.kg
-1] 
•  D = Daily dose of the active ingredient [mg.kgbw
-1.d
-1] 
•  Ad = Number of day of treatment [d] 
•  BW = Animal body weight [kgbw.animal
-1] (see Table 4.) 
•  SD = Stocking density [animal.ha
-1] (see Table 4.) 
•  Fh = Fraction of herd treated [value between 0 and 1] (see 
Table 2.) 
•  1500 = Bulk density of dry soil [kg.m
-3] 
•  10000 = Area of 1 hectare [m
2.ha
-1] 
•  0.05 = Depth of penetration into soil [m] 
•  1000 = Conversion factor [1000 µg.mg
-1] 
 
 
Table 4. 
Default values for use in calculating the PECsoil for pasture animals 
 
Animal type  Stocking density 
(animals.ha
-1)
1 
Bodyweight 
(kgbw)
2,3 
Dairy cow   3.5  600 
Beef cattle   9.5  330 
Sheep (adult ewe)   15  80 
Lambs   25  36 
Horse   3  600 
Pony   5  250 
Goat   15  60 
 
5. Phase II 
 
The aim of the Phase II (and in Phase I) 
is to assess the potential for VMPs to affect 
non-target species in the environment. It is 
not possible to evaluate the effects of VMPs 
on every species in the environment that 
78 Ioana Valentina Tihulca                                                                                                                    Medicamentul Veterinar / Veterinary Drug 
 
                                                                                                                                                                                     Vol. 7(1). May - June 2013 
 
77 
 
may be exposed to the VMP following its 
administration to the target species.  
The taxonomic levels tested are 
intended to serve as surrogates or indicators 
for the range of species present in the 
environment. 
It is used a two-tiered approach to the 
environmental risk assessment.  
The first tier, Tier A, makes use of 
simpler, less expensive studies to produce a 
conservative assessment of risk based on 
exposure and effects in the environmental 
compartment of concern.  
If the ERA cannot be completed with 
such data, due to a prediction of 
unacceptable risk, then the applicant 
progresses to Tier B to refine the ERA.  
In some cases, it may be possible to 
implement a risk management option 
instead of moving to Tier B. 
At the beginning of Phase II a Tier A 
base data set on the fate and effects of the 
VMP is produced by the applicant.  
This data set is a key element of the 
assessment procedure allowing for the rapid 
identification of hazards and/or risks 
associated with the use of the product. 
At this point, it is important to make use 
of all available documentation relevant to the 
environmental risk assessment of the 
product. This includes physico-chemical 
data, relevant pharmacological toxicological 
and toxicokinetic studies and information on 
degradability or persistence of the active 
ingredient under relevant conditions.  
These properties will vary between the 
parent compound and  the individual 
excreted metabolites, for example, the latter 
may be more water-soluble than the parent 
compound and may be more mobile and/or 
more persistent in the environment. 
Consideration of the excretion data is 
not initially recommended at Tier A, where a 
total residue approach should be taken and 
a PEC initial should be estimated. It should 
be assumed that the VMP is excreted 100% 
as parent. 
The specific test guidelines / protocols 
recommended in Phase II are those finalized 
by OECD/ISO. This has the advantage of 
ensuring that environmental studies are 
current and broadly acceptable to regulatory 
authorities on a worldwide basis.  
Finally, conducting ERA studies in 
accordance with Good Laboratory Practice 
(GLP) is a regional requirement and if 
studies are not conducted to GLP, they may 
not be accepted in some VICH regions. 
 
PEC refinement 
 
In Phase II Tier A the PECs are initially 
calculated based on the total residue 
approach and compared with the PNEC 
derived from the base set of toxicity tests. If 
the RQ is above one, the adjustments 
presented below can be used to refine the 
PECs. 
Depending upon the scenario and the 
characteristics of the active ingredient being 
studied, a number of options may be 
available to refine the exposure assessment. 
Broadly speaking, these refinements fall into 
one or more of the following categories: 
• Refinement based on metabolism 
•  Refinement based on the excretion 
pattern 
• Refinement based on degradation in 
manure/slurry 
• Refinement based on degradation in 
soil 
 
Risk Quotient (RQ) Approach 
 
The ERA is based on the accepted 
principle that risk is a product of the 
exposure, fate and effects assessments of 
the  VMP  for  the  environmental 
compartments of concern. The Phase II ERA 
is based on a RQ approach, which is the 
ratio of  the predicted environmental 
concentration (PEC) and the predicted no 
effect concentration (PNEC) on non-target 
organisms.  The  RQ  (PEC/PNEC)  is 
compared against a value of one, and a 
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value less than one indicates that no further 
testing is recommended.  
The PEC of the RQ is defined as the 
concentration of the parent compound and 
metabolites predicted to be present in the 
soil, water and sediment compartment.  
The PNEC of the RQ is determined from 
the  experimentally  determined  effects 
endpoint divided  by an  appropriate 
assessment factor (AF).  
The AF is intended to cover 
uncertainties such as intra- and inter-
laboratory and species variation, the need to 
extrapolate from laboratory study results to 
the field, and from short term to long term 
toxicity (acute:chronic ratios).  
The value varies depending on the type 
of study conducted. If the RQ is 1 for one 
or more tested taxonomic levels, then 
metabolism/excretion data from the residues 
and Absorption, Distribution, Metabolism, 
Excretion (ADME) part of the dossier should 
be considered as part of the PEC 
refinement.  Excreted  metabolites 
representing 10% or more of the 
administered dose and which do not form 
part of biochemical pathways should be 
added to the active substance to allow the 
PEC to be recalculated. 
If the RQ is still 1 after PEC refinement 
and testing at Tier B, then guidance should 
be sought from the regulatory authority, 
including whether testing of the major 
environmentally relevant metabolites needs 
to be considered. 
 
Tier B Testing - Environmental Fate 
Studies 
 
If the log Kow is 4, evidence from 
absorption, distribution, metabolism and 
excretion  (ADME)  and  biodegradation 
studies and molecular mass should be 
considered to see whether there is the 
potential for bioaccumulation to occur. If so, 
then a bioconcentration factor (BCF) study is 
recommended to be carried out at Tier B. 
Evidence of bioaccumulation from ADME 
studies would be the presence of high 
concentrations of the active in fat compared 
to other tissues and/or the slow depletion of 
the residue from fat tissue. In view of the fact 
that in general the activity of enzymes 
involved in the transformation of xenobiotics 
decrease at lower trophic levels, the lack of 
accumulation  in  mammals does not 
automatically exclude the potential for 
accumulation in fish. 
If there is still an indication of risk on 
completion of the Tier B assessment, e.g. for 
VMPs which still have an RQ >1 or the BCF 
 1000, then the applicant is recommended 
to discuss their dossier and proposals for 
further data or risk mitigation with the 
regulatory authority. 
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